AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models

BACKGROUND: Treatments that generate T cell-mediated immunity to a patient’s unique neoantigens are the current holy grail of cancer immunotherapy. In particular, treatments that do not require cumbersome and individualized ex vivo processing or manufacturing processes are especially sought after. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaw, Stephen M., Middleton, Jenny, Wigglesworth, Kim, Charlemagne, Amber, Schulz, Oliver, Glossop, Melanie S., Whalen, Giles F., Old, Robert, Westby, Mike, Pickford, Chris, Tabakman, Rinat, Carmi-Levy, Irit, Vainstein, Abi, Sorani, Ella, Zur, Arik A., Kristian, Sascha A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923872/
https://www.ncbi.nlm.nih.gov/pubmed/31889898
http://dx.doi.org/10.1186/s12935-019-1059-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923872/
https://www.ncbi.nlm.nih.gov/pubmed/31889898
http://dx.doi.org/10.1186/s12935-019-1059-8

Ejemplares similares